Role of the IgE-mediated system in eosinophil recruitment triggered by two consecutive cycles of sensitisation and challenge in rats.
In this study, we postulated that repeated cycles of IgE passive sensitisation and antigen challenge may play a role in up-regulating eosinophil response in allergic conditions. Antigen-mediated stimulation of the pleural cavity of rats passively sensitised with a single injection of IgE anti-DNP resulted in mast cell degranulation, increase in vascular permeability and mild neutrophilia, but no pleural eosinophilia. In contrast, a second cycle of sensitisation and challenge, performed within 7 days, showed a marked eosinophilia in parallel with a lower plasma leakage and comparable neutrophilia. The eosinophilic phenomenon was not reproduced when (1) IgE sensitisation or antigen challenge was omitted in the first cycle, or (2) the first cycle was replaced by either a histamine and 5-HT dual challenge or a PAF challenge. Furthermore, we found an increase in eotaxin levels in animals subjected to two rather than one cycle of sensitisation and challenge. Treatment with the PAF receptor antagonist BN 52021 or with the lipoxygenase inhibitor zileuton, but not mast cell granule depletion, prevented the allergen-evoked eosinophil accumulation in rechallenged animals. Our results indicate that repeated cycles of IgE-driven inflammation may lead to eosinophil accumulation in a mechanism dependent on eotaxin, PAF and leukotrienes.
Calheiros
A S
AS
Departamento de Fisiologia e Farmacodinâmica, Instituto Oswaldo Cruz - IOC/FIOCRUZ, Rio de Janeiro, Brasil.
Aguiar Pires
A L
AL
Pereira da Silva
J
J
Cordeiro
R S
RS
Martins
M A
MA
Lima
M C
MC
D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology*; D001094:Arachidonate 5-Lipoxygenase / Q000378:metabolism; D054413:Chemokine CCL11; D019742:Chemokines, CC / Q000378:metabolism; D004140:Dinitrophenols / Q000008:administration & dosage / Q000276:immunology*; D004334:Drug Administration Schedule; D004802:Eosinophilia / Q000276:immunology*; D004804:Eosinophils / Q000276:immunology; D006632:Histamine / Q000494:pharmacology; D007116:Immunization, Passive; D007073:Immunoglobulin E / Q000008:administration & dosage / Q000276:immunology*; D018836:Inflammation Mediators / Q000378:metabolism; D008407:Mast Cells / Q000276:immunology; D010998:Pleurisy / Q000276:immunology*; D051381:Rats; D017208:Rats, Wistar; D012710:Serum Albumin, Bovine / Q000008:administration & dosage / Q000276:immunology*
D000911:Antibodies, Monoclonal; C515458:Ccl11 protein, rat; D054413:Chemokine CCL11; D019742:Chemokines, CC; D004140:Dinitrophenols; D018836:Inflammation Mediators; C034638:dinitrophenyl-bovine serum albumin; D012710:Serum Albumin, Bovine; D007073:Immunoglobulin E; D006632:Histamine; D001094:Arachidonate 5-Lipoxygenase